Shionogi & Co., Ltd. (TYO:4507)
Market Cap | 2.21T |
Revenue (ttm) | 440.50B |
Net Income (ttm) | 179.12B |
Shares Out | 850.98M |
EPS (ttm) | 210.53 |
PE Ratio | 12.34 |
Forward PE | 12.18 |
Dividend | 66.00 (2.55%) |
Ex-Dividend Date | Sep 29, 2025 |
Volume | 614,200 |
Average Volume | 2,063,050 |
Open | 2,597.00 |
Previous Close | 2,598.50 |
Day's Range | 2,595.00 - 2,653.50 |
52-Week Range | 2,028.50 - 2,724.00 |
Beta | 0.14 |
RSI | 54.58 |
Earnings Date | Oct 27, 2025 |
About Shionogi &
Shionogi & Co., Ltd. researches, develops, manufactures, and distributes pharmaceuticals, diagnostic reagents, and medical devices. It offers and develops drugs in the areas of infectious diseases, COVID-19, tumors, sclerosis, pomp, fragile X syndrome, and other diseases. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan. [Read more]
Full Company ProfileFinancial Performance
In 2024, Shionogi &'s revenue was 438.27 billion, an increase of 0.73% compared to the previous year's 435.08 billion. Earnings were 170.44 billion, an increase of 5.19%.
Financial StatementsNews
Shionogi & Co., Ltd. 2025 Q1 - Results - Earnings Call Presentation

Shionogi & Co., Ltd. (SGIOY) Q1 2025 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q1 2025 Earnings Conference Call July 28, 2025 3:30 AM ET Company Participants John A.
Shionogi & Co. reports Q1 results
Shionogi & Co. GAAP EPS of ¥200.29, revenue of ¥438.27B
Shionogi to buy Japan Tobacco’s Torii Pharma in a deal worth over $1B
Shionogi and Jordan's Guardian Angels Announce First-Ever Human Drug Study for Jordan's Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder
Large-Scale Research and Grassroots Patient Advocacy Collaborations Led to Historic Milestone for Rare Disease Community Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshir...
Shionogi & Co., Ltd. 2024 Q3 - Results - Earnings Call Presentation
Shionogi targets JPY550B revenue through QOL focus and global expansion
Shionogi & Co., Ltd. (SGIOY) Q3 2024 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q3 2024 Earnings Conference Call January 31, 2025 3:30 AM ETCompany ParticipantsYoshimasa Kyokawa - VP, Corporate...
Shionogi & Co. reports 9M results

Shionogi & Co., Ltd. (SGIOY) Q2 2024 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q2 2024 Earnings Call Transcript October 29, 2024 2:00 AM ET Company Participants Yoshimasa Kyokawa - Vice President, Corporate Communications Isao Teshirogi - Chair...

Antibiotics, an important but tricky business, says Shionogi CEO [Advocacy Lab Content]
Producing antibiotics remains imperative but production is hindered by an unattractive business model, says Shionogi CEO. Pull incentives are needed to ensure safe, global supplies of vital drugs.

Shionogi & Co., Ltd. (SGIOY) Q1 2024 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q1 2024 Earnings Conference Call July 29, 2024 4:00 AM ET Company Participants Yoshimasa Kyokawa - Vice President, Corporate Communications Masako Kudou - Vice Presi...

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
OSAKA, Japan & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) and Maze Therapeutic...

Shionogi & Co., Ltd. (SGIOF) Q2 2023 Earnings Conference Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOF) Q2 2023 Earnings Conference Call October 31, 2023 9:30 PM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications Isao Teshirogi - Representative Di...

Shionogi & Co., Ltd. (SGIOF) Q1 2023 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOF) Q1 2023 Earnings Conference Call July 31, 2023 5:15 AM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications John Keller - Senior Executive Office...

Shionogi: Likely The Last Viable COVID Play
Xocova is an approved-in-Japan COVID antiviral. Other COVID investments are causing valuations to fall as their opportunities subside.

Shionogi & Co., Ltd. (SGIOF) Q3 2022 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOF) Q3 2022 Earnings Conference Call January 30, 2023 1:00 AM ET Company Participants Yoshimasa Kyokawa - Investor Relations Masako Kudou - Vice President, Finance and A...